Nature Search

A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes

Jannie Borst
René J. van de Griend
Reinder L. H. Bolhuis
Research19 Feb 1987
Nature

Volume: 325, P: 683-688
Lymphocytotoxic antibodies produced by H—2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype

Pavol Ivanyi
Cornelis J. M. Melief
Paul de Greeve
Research20 Dec 1979
Nature

Volume: 282, P: 843-844
Peptide selection by MHC class I molecules

Ton N. M. Schumacher
Marloes L. H. De Bruijn
Hidde L. Ploegh
Research25 Apr 1991
Nature

Volume: 350, P: 703-706
T cell depletion in transgenic mice carrying a mutant gene for TCR-β

Paul Krimpenfort
Ferry Ossendorp
Anton Berns
Research26 Oct 1989
Nature

Volume: 341, P: 742-746
Abolition of specific immune response defect by immunization with dendritic cells

Claire J. P. Boog
W. Martin Kast
Cornelis J. M. Melief
Research01 Nov 1985
Nature

Volume: 318, P: 59-62
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

Linda Diehl
Annemieke Th. den Boer
Rene E. M. Toes
Research01 Jul 1999
Nature Medicine

Volume: 5, P: 774-779
Immune pact with the enemy

Progress comes from the latest investigations into a long-standing question in immunology — the role of the immune system in maintaining small, potentially cancerous lesions in a state of dormancy.

Cornelis J. M. Melief
News & Views18 Nov 2007
Nature

Volume: 450, P: 803-804
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes

Peptides presented to cytotoxic T lymphocytes are typically generated by proteasome action. Kessler and colleagues show that the cytosolic endopeptidases nardilysin and thimet oligopeptidase generate the C termini of tumor-relevant epitopes.

Jan H Kessler
Selina Khan
Cornelis J M Melief
Research12 Dec 2010
Nature Immunology

Volume: 12, P: 45-53
C₃-symmetric peptide scaffolds are functional mimetics of trimeric CD40L

Sylvie Fournel
Sébastien Wieckowski
Gilles Guichard
Research06 Nov 2005
Nature Chemical Biology

Volume: 1, P: 377-382
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

Stephen P. Schoenberger
Rene E. M. Toes
Cornelis J. M. Melief
Research04 Jun 1998
Nature

Volume: 393, P: 480-483
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

Vaccination regimens and the number of doses required for optimal immunity and protection are critical factors in the translation of vaccines. Here the authors show administration of a three dose protocol of a single T cell epitope to the SARS-CoV-2 spike protein induces a robust CD8⁺ T cell response and confers protection in a lethal murine challenge model of infection.

Iris N. Pardieck
Tetje C. van der Sluis
Ramon Arens
ResearchOpen Access08 Jul 2022
Nature Communications

Volume: 13, P: 1-11
Smart delivery of vaccines

A strategy to enhance antigen immunogenicity was developed by adsorption of polyethyleneimine on a mesoporous silica microrod vaccine for the presentation of tumour viruses and neoantigens, demonstrating their ability to drive anti-tumour immunity.

Cornelis J. M. Melief
News & Views23 May 2018
Nature Materials

Volume: 17, P: 482-483
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation

Human papillomavirus employs immune evasion strategies to establish a long-term infection. Here the authors show that the virus in the EGFR-dependent manner induces IFRD1, which blocks NFκB activating acetylation, and that this process can be suppressed by the EGFR inhibitor cetuximab.

Bart Tummers
Renske Goedemans
Sjoerd H. van der Burg
ResearchOpen Access13 Mar 2015
Nature Communications

Volume: 6, P: 1-12
Precision T-cell therapy targets tumours

The T cells of the immune system can destroy tumours, but their activation can be inefficient. Vaccines that exploit tumour mutations elicit robust T-cell responses to tumours, with potential clinical benefits. See Letters p.217 & p.222

Cornelis J. M. Melief
News & Views05 Jul 2017
Nature

Volume: 547, P: 165-167
Cat and mouse games

The immune system is intimately involved in how tumours develop. But how do tumours avoid being killed by immune responses? It seems that in some instances they can lull immune cells into a false sense of security.

Cornelis J. M. Melief
News & Views31 Aug 2005
Nature

Volume: 437, P: 41-42
Dendritic cell immunotherapy: mapping the way

Carl G Figdor
I Jolanda M de Vries
Cornelis J M Melief
Reviews30 Apr 2004
Nature Medicine

Volume: 10, P: 475-480
Vaccines for established cancer: overcoming the challenges posed by immune evasion

This Review summarizes immune evasion mechanisms that limit the therapeutic efficacy of cancer vaccines. The authors discuss how improving vaccine design and using vaccines in combination with other anticancer therapies can boost treatment efficacy in patients with established cancers.

Sjoerd H. van der Burg
Ramon Arens
Cornelis J. M. Melief
Reviews11 Mar 2016
Nature Reviews Cancer

Volume: 16, P: 219-233
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

Thorbald van Hall
Elisabeth Z Wolpert
Rienk Offringa
Research19 Mar 2006
Nature Medicine

Volume: 12, P: 417-424
Escort service for cross-priming

Cross-priming of cytotoxic T cells requires the transfer of antigens to dendritic cells from other cells. Careful analysis indicates that the antigens are peptides in association with chaperone proteins.

Cornelis J M Melief
News & Views01 Jun 2005
Nature Immunology

Volume: 6, P: 543-544
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

This Review discusses the recent progress in the treatment of established (pre)malignant disease of viral or non-viral origin with synthetic long peptide vaccines that are capable of inducing robust T-cell responses.

Cornelis J.M. Melief
Sjoerd H. van der Burg
Reviews01 May 2008
Nature Reviews Cancer

Volume: 8, P: 351-360
Therapeutic cancer vaccines

This Review broadly discusses therapeutic cancer vaccines, covering resistance mechanisms and strategies to overcome these, how to improve the antigen repertoire for vaccines and vaccine platforms, and approaches for enhancing immunotherapy efficacy.

Mansi Saxena
Sjoerd H. van der Burg
Nina Bhardwaj
Reviews27 Apr 2021
Nature Reviews Cancer

Volume: 21, P: 360-378
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

A carcinogen-induced mouse tumour model is used here to show that mutant tumour-specific antigens are targets for CD8⁺ T-cell responses, mediating tumour regression after checkpoint blockade immunotherapy, and that these antigens can be used effectively in therapeutic vaccines; this advance potentially opens the door to personalized cancer vaccines.

Matthew M. Gubin
Xiuli Zhang
Robert D. Schreiber
Research26 Nov 2014
Nature

Volume: 515, P: 577-581
CD4⁺ T cell help in cancer immunology and immunotherapy

CD4⁺ T cells provide help to CD8⁺ T cells via lymph node-resident dendritic cells. In this Review, the authors discuss the molecular nature of help signals and how they can be harnessed to improve cancer immunotherapy.

Jannie Borst
Tomasz Ahrends
Wolfgang Kastenmüller
Reviews29 Jul 2018
Nature Reviews Immunology

Volume: 18, P: 635-647
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

Anand G Menon
Peter J K Kuppen
Cornelis J H van de Velde
Research30 Jun 2003
Cancer Gene Therapy

Volume: 10, P: 509-517
Immunogenetics: Safety in numbers

Cornelis J M Melief
News11 May 2005
European Journal of Human Genetics

Volume: 13, P: 795-796

Search

A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes

Lymphocytotoxic antibodies produced by H—2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype

Peptide selection by MHC class I molecules

T cell depletion in transgenic mice carrying a mutant gene for TCR-β

Abolition of specific immune response defect by immunization with dendritic cells

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

Immune pact with the enemy

Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes

C₃-symmetric peptide scaffolds are functional mimetics of trimeric CD40L

T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection

Smart delivery of vaccines

The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation

Precision T-cell therapy targets tumours

Cat and mouse games

Dendritic cell immunotherapy: mapping the way

Vaccines for established cancer: overcoming the challenges posed by immune evasion

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

Escort service for cross-priming

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

Therapeutic cancer vaccines

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

CD4⁺ T cell help in cancer immunology and immunotherapy

Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

Immunogenetics: Safety in numbers

Search

Quick links

Search

Filter By:

Search

Quick links